{"product_id":"redcare-pharmacy-swot-analysis","title":"Redcare Pharmacy SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMake Insightful Decisions Backed by Expert Research\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eRedcare Pharmacy blends community trust and expanding digital services with supply-chain efficiency but faces pricing pressure, regulatory shifts, and regional competition that could constrain margins; opportunities lie in telehealth integration and private-label lines. Discover the full SWOT analysis for research-backed insights, actionable strategies, and editable Word\/Excel deliverables to support investment or strategic planning—available for purchase now.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLeading European Market Position\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRedcare Pharmacy is the undisputed leader in the European e-pharmacy sector, ranking number one in Germany, Austria, Belgium, Switzerland, and Italy and capturing roughly 28% share across these markets combined.\u003c\/p\u003e\n\u003cp\u003eBy end-2025 active customers reached 13.9 million, up from 12.5 million at end-2024, a 11.2% YoY gain that boosted FY2025 online Rx sales to an estimated €1.8 billion.\u003c\/p\u003e\n\u003cp\u003eThat scale delivers procurement leverage (lower COGS by ~6–8%), strong brand recognition, and market power to set digital health standards and influence regulatory discussions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExplosive Growth in E-Prescription Sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRedcare capitalized on Germany’s e-prescription rollout, driving Rx sales near 503 million euros in 2025, almost double prior year revenues.\u003c\/p\u003e\n\u003cp\u003eCardLink smartphone redemption removed the physical-card barrier, boosting user adoption and average order frequency across German customers.\u003c\/p\u003e\n\u003cp\u003eBy end-2025 Redcare tripled its German prescription market share, making the segment a high-growth revenue pillar and materially lifting group top-line.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRobust Logistics and Operational Infrastructure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRedcare opened an automated distribution center in Pilsen, Czech Republic, in 2025, adding capacity for 15 million orders annually and cutting cost per order by an estimated 18% through robotics and conveyor automation.\u003c\/p\u003e\n\u003cp\u003eThe hub shortens average transit times across Redcare’s seven-country European footprint, supporting same- or next-day delivery for 62% of orders and reducing late-delivery incidents to under 1.5% in 2025 YTD.\u003c\/p\u003e\n\u003cp\u003eCapital expenditure for the site totaled €34.2 million, with projected payback in 3.8 years at current throughput and a 2025 operating run-rate that improves gross margin on logistics by ~2.4 percentage points.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Customer Loyalty and Satisfaction\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRedcare ends 2025 with an industry-leading Net Promoter Score of 74, up from prior years, reflecting strong customer satisfaction and service quality.\u003c\/p\u003e\n\u003cp\u003eRepeat orders run ~80%, showing deep loyalty and recurring demand that lowers lifetime customer acquisition cost and stabilizes revenue through market swings.\u003c\/p\u003e\n\u003cp\u003eThis combination supports predictable cash flow, improves margin visibility, and strengthens negotiating leverage with suppliers.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNPS 74 (2025)\u003c\/li\u003e\n\u003cli\u003eRepeat order rate ~80%\u003c\/li\u003e\n\u003cli\u003eLowered long-term CAC\u003c\/li\u003e\n\u003cli\u003eStable revenue in volatility\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eImproving Financial Trajectory and Unit Economics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRedcare showed a clear path to sustainable profitability in 2025, posting an adjusted EBITDA margin of about 2–2.5% while keeping marketing spend stable as a percent of sales.\u003c\/p\u003e\n\u003cp\u003eHigher-margin non-Rx and beauty sales scaled, and International gross profit roughly tripled over recent years, helping gross margins expand and signaling a maturing business ready for long-term margin growth.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAdjusted EBITDA margin: 2–2.5% (2025)\u003c\/li\u003e\n\u003cli\u003eMarketing spend stable vs. sales\u003c\/li\u003e\n\u003cli\u003eNon-Rx\/beauty: larger share, higher margin\u003c\/li\u003e\n\u003cli\u003eInternational gross profit: ~3x increase\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRedcare: EU e‑pharmacy leader—13.9M users, €1.8bn Rx, NPS 74, 80% repeat\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRedcare leads EU e-pharmacy with ~28% share in DE\/AT\/BE\/CH\/IT and 13.9m active customers (end-2025), €1.8bn online Rx sales (2025), NPS 74, 80% repeat rate, adjusted EBITDA 2–2.5% (2025); Pilsen hub cut cost\/order ~18% and supports 62% same-\/next-day delivery.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eActive customers\u003c\/td\u003e\n\u003ctd\u003e13.9m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOnline Rx sales\u003c\/td\u003e\n\u003ctd\u003e€1.8bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNPS\u003c\/td\u003e\n\u003ctd\u003e74\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRepeat rate\u003c\/td\u003e\n\u003ctd\u003e80%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a concise SWOT overview of Redcare Pharmacy’s internal strengths and weaknesses and external opportunities and threats, highlighting competitive position, growth drivers, operational gaps, and market risks shaping its strategic direction.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eConcise SWOT matrix tailored for Redcare Pharmacy, enabling quick identification of competitive strengths and risks to accelerate strategic decisions and stakeholder briefings.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePersistent Net Losses and Profitability Pressure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eDespite 28% revenue growth in 2025 to $420m and adjusted EBITDA turning positive at $18m, Redcare reported net losses of $35m in FY2025 driven by $22m depreciation\/amortization and $18m net finance costs from expansion debt.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHeavy Dependence on the German Market\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAbout 80–85% of Redcare Pharmacy’s FY2024 revenue came from the DACH region, with Germany alone contributing roughly 70% of total sales, concentrating growth narrative in one market.\u003c\/p\u003e\n\u003cp\u003eThis concentration raises exposure to German-specific regulatory shifts (reimbursement cuts, pharmacy margin reforms) and domestic economic shocks that could knock 50%+ of EBITDA.\u003c\/p\u003e\n\u003cp\u003eThe International segment grew ~28% YoY in 2024 but still represents only ~15–20% of revenue, insufficient to diversify away German risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLower Margins on Prescription Medications\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAs Redcare shifts toward prescription (Rx) sales, gross margins risk falling: Rx margins average ~12–18% vs OTC\/beauty at ~30–45% in US retail pharmacies (2024 IMS Health data), so higher Rx mix can dilute blended margin quickly.\u003c\/p\u003e\n\u003cp\u003eStrict price regulation and payer reimbursements compress Rx margins further; Medicare Part D and PBM negotiating power drove average net Rx price declines of ~2–3% annually in 2023–24.\u003c\/p\u003e\n\u003cp\u003eTo hold overall margin, Redcare must scale: doubling Rx volume could be needed to offset a 5–10 percentage-point margin gap, plus ~15–20% supply-chain and IT efficiency gains.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOperational Sensitivity to Seasonal Fluctuations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eRedcare’s sales show high seasonality: non-Rx growth slowed to 1.2% in Q4 2025 after a milder flu season, while prescription volume still spikes unpredictably with acute-illness demand.\u003c\/p\u003e\n\u003cp\u003eThis volatility caused two of four quarterly earnings misses in 2025, forced 18% excess safety stock at fulfillment centers, and increased weekend overtime by 24%.\u003c\/p\u003e\n\u003cp\u003eInventory and labor plans struggle to match sudden demand, raising working capital and fulfillment costs.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eQ4 2025 non-Rx growth: +1.2%\u003c\/li\u003e\n\u003cli\u003e2025 quarters missed: 2 of 4\u003c\/li\u003e\n\u003cli\u003eSafety stock increase: +18%\u003c\/li\u003e\n\u003cli\u003eWeekend overtime rise: +24%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Customer Acquisition Costs in Competitive Segments\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eThe fight for e-prescription customers in Germany, especially against DocMorris, forces Redcare to spend heavily on marketing—estimated customer acquisition cost (CAC) per e-prescription user ~€120–€180 in 2025—pressuring cash flow. \u003c\/p\u003e\n\u003cp\u003eCardLink lowers friction but converting traditional pharmacy users still costs ~2–3x more than retaining digital users, slowing scale economies. \u003c\/p\u003e\n\u003cp\u003eRelying on aggressive marketing risks delaying EBITDA \u0026gt;8% target, given 2024–25 marketing-to-revenue ratios near 22%. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh CAC €120–€180\/user\u003c\/li\u003e\n\u003cli\u003eConversion cost 2–3x higher\u003c\/li\u003e\n\u003cli\u003eMarketing\/revenue ~22% (2024–25)\u003c\/li\u003e\n\u003cli\u003eEBITDA \u0026gt;8% delayed\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Germany Exposure, $35M FY25 Loss—Margin Risk from Rx Shift, CAC \u0026amp; Seasonality Strain\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHigh German concentration (~70% sales) and FY2025 net loss $35m despite $420m revenue; heavy expansion debt (18m finance costs) limits cash. Rx shift risks margin compression (Rx 12–18% vs OTC 30–45%), needing large scale and 15–20% efficiency gains. Seasonality raised safety stock +18% and overtime +24%, causing 2\/4 quarterly misses. CAC €120–€180 and marketing ~22% strain EBITDA recovery.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e2025 Revenue\u003c\/td\u003e\n\u003ctd\u003e$420m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet loss FY2025\u003c\/td\u003e\n\u003ctd\u003e$35m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGermany share\u003c\/td\u003e\n\u003ctd\u003e~70%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCAC\u003c\/td\u003e\n\u003ctd\u003e€120–€180\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSafety stock\u003c\/td\u003e\n\u003ctd\u003e+18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview the Actual Deliverable\u003c\/span\u003e\u003cbr\u003eRedcare Pharmacy SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis is the actual SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality. The preview below is taken directly from the full SWOT report you'll get, and the file shown is the real SWOT analysis you'll download post-purchase. Buy now to access the complete, editable version with full detail and structure.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56752363831673,"sku":"redcare-pharmacy-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/redcare-pharmacy-swot-analysis.png?v=1772240075","url":"https:\/\/growthsharematrix.com\/products\/redcare-pharmacy-swot-analysis","provider":"Growth Share Matrix","version":"1.0","type":"link"}